Pathway Research (Pathway Rx) is a research company dedicated to studying the effectiveness of cannabis compounds and developing custom cannabis therapies aimed at treating specific ailments and diseases. Pathway Rx Founder and CEO, Dr. Igor Kovalchuk is an award-winning expert in genetics and molecular biology and is one of the first researchers to be granted a Health Canada cannabis research license.
Pathway Rx operates in partnership with the University of Lethbridge and other companies including Swysh Inc., an oral health product developer, InPlanta Biotechnology, a licensed cannabis nursery that generated over 1,000 hybrids, and Sundial Growers (“Nasdaq: SNDL”), an Alberta-based licensed cannabis producer.
Company Details
- Employees
- 6
- Industry
- Research Services
- NAICS
-
Scientific Research and Development ServicesResearch and Development in the Physical, Engineering, and Life SciencesResearch and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Website
- pathwayresearch.ca
Pathway Rx Questions
Pathway Rx's website is pathwayresearch.ca
Pathway Rx's LinkedIn profile is https://ca.linkedin.com/company/pathway-rx
Pathway Rx has
6 employees.
View email and phone details for 6
employees at Pathway Rx.
Pathway Rx's industry is
Research Services
Pathway Rx's top competitors are
True Health,
Canadian School Of Hydrocarbon Measurement,
Circe Ltd - Epigenetic Therapies For Oncology,
Rxpathways,
Vita Genesis,
Institut De Radioprotection Et De Surete Nucleaire,
Alpha Cure Therapeutics,
Ingene Diagnostics S.l.,
Mirablue Bio,
Echidna Therapeutics.
Pathway Rx's categories are Research Services
